Results 21 to 30 of about 304,614 (388)

EGF Receptor Transactivation by Endothelin-1 Increased CHSY-1 Mediated by NADPH Oxidase and Phosphorylation of ERK1/2 [PDF]

Cell Journal, 2021
Objective: Growth factors [transforming growth factor-β (TGF-β), epidermal growth factor (EGF), endothelin-1 (ET-1)] stimulate proteoglycan synthesis resulting in retention and accumulation of low density lipoprotein (LDL) in vessel intima and leading to
Hossein Babaahmadi-Rezaei, Alireza Kheirollah, Mojtaba Rashidi, Faezeh Seif, Zahra Niknam, Masoumeh Zamanpour   +5 more
doaj   +1 more source

The Effect of Endothelin-1 on Gene Expression of Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidase via Transforming Growth Factor Beta (TGF–β) Receptor in Human Aortic Smooth Muscle Cells

مجله دانشکده پزشکی اصفهان, 2018
Background: Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Nox) is one of the predominant sources of the production of free oxygen radicals in the vascular wall.
Parisa Dayati, Reyhaneh Niayesh-Mehr, Alireza Jafari, Hossein Babaahmadi-Rezaei   +3 more
doaj   +1 more source

Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension

Respiratory Research, 2011
Background Endothelin-1 signalling plays an important role in pathogenesis of pulmonary hypertension. Although different endothelin-A receptor antagonists are developed, a novel therapeutic option to cure the disease is still needed.
Brandes Ralf P, Janssen Wiebke, Cornitescu Teodora, Sydykov Akylbek, Dahal Bhola K, Luitel Himal, Kojonazarov Baktybek, Kosanovic Djuro, Davie Neil, Ghofrani Hossein A, Weissmann Norbert, Grimminger Friedrich, Seeger Werner, Schermuly Ralph T   +13 more
doaj   +1 more source

Comparative effectiveness of endothelin receptor antagonists on mortality in patients with pulmonary arterial hypertension in a US Medicare population: a retrospective database analysis

Pulmonary Circulation, 2020
Limited evidence is available on outcomes associated with currently available medications from the endothelin receptor antagonist drug class (bosentan, ambrisentan, and macitentan) in elderly patients with pulmonary arterial hypertension.
Raymond L. Benza, Cassandra A. Lickert, Lin Xie, William Drake, Adesuwa Ogbomo, Huseyin Yuce, Michele R. Cole   +6 more
doaj   +1 more source

Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia.

Journal of the American Society of Nephrology, 2016
AKI is associated with high mortality rates and the development of CKD. Ischemia/reperfusion (IR) is an important cause of AKI. Unfortunately, there is no available pharmacologic approach to prevent or limit renal IR injury in common clinical practice ...
J. Barrera-Chimal, S. Prince, F. Fadel, Soumaya El Moghrabi, D. Warnock, P. Kolkhof, F. Jaisser   +6 more
semanticscholar   +1 more source

Pharmacological Potential of Endothelin Receptors Agonists and Antagonists

Acta Medica, 2005
Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified.
Jiří Patočka, Vladimír Měrka, Vratislav Hrdina, Radomír Hrdina   +3 more
doaj   +1 more source

Communication over the network of binary switches regulates the activation of A$_{2A}$ adenosine receptor [PDF]

PLoS Comp. Biol. (2015) 11(2): e1004044, 2014
Dynamics and functions of G-protein coupled receptors (GPCRs) are accurately regulated by the type of ligands that bind to the orthosteric or allosteric binding sites. To glean the structural and dynamical origin of ligand-dependent modulation of GPCR activity, we performed total $\sim$ 5 $\mu$sec molecular dynamics simulations of A$_{2A}$ adenosine ...
arxiv   +1 more source

Endothelin-1 Drives Epithelial-Mesenchymal Transition In Hypertensive Nephroangiosclerosis [PDF]

, 2016
BACKGROUND: Tubulointerstitial fibrosis, the final outcome of most kidney diseases, involves activation of epithelial mesenchymal transition (EMT). Endothelin‐1 (ET‐1) activates EMT in cancer cells, but it is not known whether it drives EMT in the kidney.
Belloni, Anna S, Buccella, Valentina, CALO', LORENZO, Caroccia, Brasilina, Gioco, Francesca, Guerzoni, Eugenia, GUIDOLIN, DIEGO, Montini, Barbara, Pagnin, Elisa, Petrelli, Lucia, Piazza, Maria, Ravarotto, Verdiana, ROSSI, GIANPAOLO, SECCIA, TERESA MARIA   +13 more
core   +1 more source

Endothelin-1, over-expressed in SOD1G93A mice, aggravates injury of NSC34-hSOD1G93A cells through complicated molecular mechanism revealed by quantitative proteomics analysis

Frontiers in Cellular Neuroscience, 2022
Endothelin-1 (ET-1), a secreted signaling peptide, is suggested to be involved in multiple actions in various tissues including the brain, but its role in amyotrophic lateral sclerosis (ALS) remains unknown.
Yingzhen Zhang, Lin Chen, Zhongzhong Li, Dongxiao Li, Yue Wu, Yansu Guo, Yansu Guo, Yansu Guo   +7 more
doaj   +1 more source

Application and Assessment of Deep Learning for the Generation of Potential NMDA Receptor Antagonists [PDF]

, 2020
Uncompetitive antagonists of the N-methyl D-aspartate receptor (NMDAR) have demonstrated therapeutic benefit in the treatment of neurological diseases such as Parkinson's and Alzheimer's, but some also cause dissociative effects that have led to the synthesis of illicit drugs.
arxiv   +1 more source